A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases
A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
Inclusion Criteria:
Exclusion Criteria:
global-roche-genentech-trials@gene.com888-662-6728 (U.S. only)
CABA, C1426AAL, Argentina
Nanjing, Jiangsu 210031, China
HangzhouZhejiang, 310009, China
Shantou, 515000, China
Paderborn, 33098, Germany
Budapest, 1082, Hungary
Meldola, Emilia-Romagna 47014, Italy
?ód?, 93-338, Poland
Olsztyn, 10-228, Poland
Wroc?aw, 53-413, Poland
Amadora-Lisbon, 2610-276, Portugal
City of Johannesburg, 2196, South Africa
Madrid, 28007, Spain
Wachira Phayaban, 10300, Thailand
Ankara, 06200, Turkey (Türkiye)
Bakirkoy / Istanbul, 34147, Turkey (Türkiye)
Bornova, Izmir, 35100, Turkey (Türkiye)
Erdine, 22030, Turkey (Türkiye)